40 µm Diameter Pore, Precision-Templated Scaffolds **Promote Infiltration of Pro-Healing Circulating Monocytes**

Nathan R. Chan^{1,2}, Billanna Hwang³, James D. Bryers^{1,2} ¹Molecular Engineering and Sciences Institute, University of Washington, Seattle, WA, 98195, USA ²Department of Bioengineering, University of Washington, Seattle, WA, 98195, USA ³Department of Surgery, University of Washington, Seattle, WA, 98195, USA





2. Objectives





🛱 Control 🛱 40 μm PTS 🛱 Monocyte-depleted 🛱 100 μm PTS

Figure 1: Flow cytometric analysis of PBMCs recovered from LysM-Cre+/0:mT/mG+/0 mice implanted subcutaneously with 40 µm PTS or 100 µm PTS, and from 40 µm PTS implanted subcutaneously in monocyte-depleted LysM-Cre+/0:mT/mG+/0 mice. (a) PBMC gating strategy. (b) Total percentage of CD14⁺ monocytes from PBMCs. (c-e) Ly6C expression of CD14⁺ monocytes at (c) Day 3, (d) Day 5, and (e) Day 7 post-scaffold implantation. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001.

Figure 4: Cytokine secretion analysis and transcriptomics on cells resident in 40 µm and 100 µm PTS explanted from untreated LysM-Cre+/0:mT/mG+/0 mice, and cells resident in 40 µm PTS explanted from monocyte-depleted LysM-Cre+/0:mT/mG+/0 mice. (a) Conditioned medium analysis of pro-inflammatory TNFa. (b) Relative expression of MARCO transcription standardized to GAPDH. (c) Polarization transcriptome gene profiling from PTS explanted 7 days post-implantation. * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001.



Track the infiltration kinetics of circulating monocytes in the peripheral blood to subcutaneously implanted 40 µm PTS and 100 µm PTS







Figure 5: Scanning electron microscopy images of subcutaneously implanted scaffolds in LysM-Cre+/:mT/mG+/0 mice at Day 3, Day 5, and Day 7 post-implantation. (a-c) 40 µm PTS in untreated mice, (d-f) 40 µm PTS in monocyte-depleted mice, and (g-i) 100 µm PTS in untreated mice.



Figure 2: Flow cytometric analysis of scaffold resident cells recovered from 40 µm PTS or 100 µm PTS implanted subcutaneously in LysM-Cre+/0:mT/mG+/0 mice, and from 40 µm PTS implanted subcutaneously in monocyte-depleted LysM-Cre+/0:mT/mG+/0 mice. (a) Gating strategy for explanted scaffold-resident cells. (b) Percentage of Myeloid EGFP+CD68+ CD14⁺ cells from explanted PTS. (c) Median fluorescent intensity of Ly6C expression from explanted PTS. * denotes p < 0.05 and ** denotes p < 0.01.



Figure 3: Representative trichrome stain of pHEMA scaffolds (40x magnification) seven days post-implantation. Collagen is stained blue, cellular cytoplasm is stained red, and nuclei are stained **black**. (a) 40 µm PTS in untreated mice, (b) 40 µm PTS in monocyte-depleted mice, and (c) 100 µm PTS in untreated mice.

5. Conclusion

- PTS generate distinct in vivo circulating blood monocyte profiles dependent on pore size
- Scaffold-resident cells appear to be derived from circulating monocytes with a statistically significant increase of infiltrating monocytes within 40 µm PTS
- 40 µm PTS contain a subset of MARCO expressing monocytes that appears to be responsible for pro-healing in 40 µm PTS
- Scaffold-resident cells exhibit unique morphological changes as a function of monocyte depletion and pore size in PTS

6. Future Experiments

- Identify specific monocyte subpopulations that give rise to a regenerative, pro-healing response in the 40 µm PTS
- Understand the mechanisms that drive favorable healing outcomes in implanted PTS